Welcome to our dedicated page for AMRS news (Ticker: AMRS), a resource for investors and traders seeking the latest updates and insights on AMRS stock.
Amyris, Inc. (AMRS) is frequently featured in news coverage for its activities as a vertically integrated synthetic biology company focused on sustainable ingredients produced via precision fermentation. Company announcements highlight developments across its Lab-to-Market™ technology platform, industrial biomanufacturing assets, strategic partnerships, and financial and operational restructuring efforts.
News about Amyris often covers its strategic transformation initiatives, including programs aimed at cost reduction, portfolio simplification, and changes to its capital structure and liquidity. The company has publicly discussed a transformation program supported by external advisors, as well as the establishment of internal governance structures to oversee these efforts. A significant news event was the commencement of voluntary Chapter 11 proceedings by Amyris and certain domestic subsidiaries, described as a step to facilitate an operational and financial restructuring centered on its core sustainable ingredients business.
Investors and observers can also find updates on Amyris’ industrial biotechnology operations, such as its precision fermentation plant in Barra Bonita, Brazil. Recent news includes Amyris taking full ownership of this plant, investing in additional fermentation capacity, and winding down a joint venture while retaining manufacturing assets and royalty interests related to specific fermented ingredients.
Another recurring theme in Amyris news is the formation and evolution of strategic partnerships and licensing agreements. Press releases describe exclusive licenses for cosmetic ingredients, long-term manufacturing agreements, and collaborations for sustainable squalene and fermented sweetener technologies. Earnings updates and revenue guidance communications provide additional context on how these partnerships, ingredient sales, and technology access activities fit into the company’s broader strategic agenda.
This news page aggregates such company-issued releases and related coverage, offering a centralized view of key developments in Amyris’ synthetic biology, fermentation, partnership, and restructuring activities over time.
Amyris, a leader in synthetic biotechnology, will host its fourth virtual investor webinar on September 28, 2021, at 1:00 PM ET. The event, titled "Lab-to-Market, Delivering Disruptive Health and Beauty Products", will cover their biotechnology platform, consumer brands, and recent executive additions. Previous webinars, held on December 15, 2020, February 9, 2021, and April 22, 2021, are available for replay. Investors can join via live webcast or call.
Amyris, a leader in synthetic biotechnology (Nasdaq: AMRS), announced its participation in two investor conferences on September 13, 2021. The H.C. Wainwright 23rd Annual Global Investment Conference will feature on-demand presentations starting at 7:00 AM ET, while the Cowen's 2nd Annual Health, Wellness & Beauty Summit will have live presentations at 2:10 PM ET. A webcast and replays will be available on the company's Investor Relations website. Amyris specializes in sustainable ingredients for health, beauty, and flavor markets.
Amyris announced the closing of its acquisition of Beauty Labs International Ltd. on August 31, enhancing its position in the clean beauty market. The acquisition integrates AI technology to improve customer experiences through personalized cosmetic recommendations. This strategic move aims to boost ecommerce revenue across Amyris brands, leveraging data science for better consumer engagement. CEO John Melo emphasized that Amyris is achieving significant revenue growth compared to peers. The integration of Beauty Labs technology is already showing promising early results, indicating potential for further growth.
Summary not available.
Amyris, Inc. (Nasdaq: AMRS) announced the closing of acquisitions of OLIKA, Inc. and MG Empower Ltd. on August 11. OLIKA is known for its clean consumer products, particularly hydrating hand sanitizers, recently expanding its retail presence. MG Empower, a digital marketing agency, partners with global brands to drive influencer marketing innovations. CEO John Melo expressed optimism about these acquisitions, indicating they will generate new revenue and enhance growth capabilities for Amyris.
Amyris, Inc. (Nasdaq: AMRS) has launched Rose Inc., a clean color cosmetics brand created in collaboration with Rosie Huntington-Whiteley. The first collection, Modern Essentials, features products that are vegan, cruelty-free, and made with sustainable ingredients like Squalane. Registration for exclusive sales opens on August 24, 2021, with a global launch on August 27, 2021. Amyris aims to set a new standard in ethical and effective beauty products, leveraging its biotechnology platform to enhance product performance and sustainability.
Amyris, Inc. (Nasdaq: AMRS) announced positive in-vivo results for its licensed RNA vaccine, developed with the Infectious Disease Research Institute (IDRI). The study demonstrated that intranasal delivery generates antibodies and provides upper respiratory protection against SARS-CoV-2, potentially enhancing immunity compared to existing vaccines. Targeted for underserved countries, this vaccine is expected to enter human trials in South Africa next year. The company continues to explore a nasal delivery system to improve accessibility and effectiveness against respiratory diseases.
Amyris, Inc. (Nasdaq: AMRS) launched Terasana™ Clinical, marking its entry into the clean skincare market. The first product, Clear + Control Healthy Skin Serum, targets dry skin and blemishes, showing a 92% reduction in blemishes in clinical trials. The serum combines Squalane and Cannabigerol (CBG), both sustainably sourced. The launch is part of a strategy to introduce three new brands this summer, projected to boost revenue significantly in the second half of the year. Terasana Clinical emphasizes clean, effective formulations and eco-friendly packaging.
Amyris, Inc. (Nasdaq: AMRS) announced the continuation of its virtual investor mini-series, themed "Delivering on the Promise of Synthetic Biology." The fourth webinar is scheduled for September 28, 2021, focusing on its innovative cannabigerol (CBG) ingredient. The company reports strong demand for its ingredients and is launching three new consumer brands this month. CEO John Melo highlighted the robust growth expected in the second half of the year driven by these new launches and accelerated sales from existing brands.
Amyris, a synthetic biotechnology firm, reported Q2 2021 financial results with total revenue of $52.3 million, a 74% increase YoY. Underlying revenue rose 41% to $42.3 million, marked by a 59% surge in consumer sales. The company achieved a GAAP net income of $15 million versus a loss of $104 million last year. Cash at quarter-end totaled $215 million. Despite increased cash operating expenses of 46%, adjusted EBITDA improved, signaling positive operational momentum. The firm anticipates revenue exceeding $400 million for the year and aims for $2 billion by 2025.